×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LLY – eli lilly and company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
10:29 am
lly
Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing Quality in Clinical Trials (London, United Kingdom - May 28-29, 2025) [Yahoo! Finance]
Low
Report
Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing Quality in Clinical Trials (London, United Kingdom - May 28-29, 2025) [Yahoo! Finance]
11/21
10:07 am
lly
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? [Yahoo! Finance]
Low
Report
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? [Yahoo! Finance]
11/21
06:20 am
lly
Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance Canada]
Low
Report
Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance Canada]
11/21
06:16 am
lly
Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance]
Low
Report
Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares [Yahoo! Finance]
11/21
04:06 am
lly
Type 2 Diabetes Pipeline Landscape Research 2024: Comprehensive Insights About 75+ Companies and 80+ Drugs [Yahoo! Finance]
Low
Report
Type 2 Diabetes Pipeline Landscape Research 2024: Comprehensive Insights About 75+ Companies and 80+ Drugs [Yahoo! Finance]
11/20
09:18 am
lly
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity [Yahoo! Finance]
Low
Report
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity [Yahoo! Finance]
11/20
07:07 am
lly
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley [Yahoo! Finance]
Low
Report
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley [Yahoo! Finance]
11/20
05:00 am
lly
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
Low
Report
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
04:30 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Walker Karen
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Walker Karen
11/20
04:29 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Sulzberger Gabrielle
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Sulzberger Gabrielle
11/20
04:28 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: LUCIANO JUAN R
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: LUCIANO JUAN R
11/20
04:27 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Kaelin William G Jr
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Kaelin William G Jr
11/20
04:26 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: JOHNSON KIMBERLY H
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: JOHNSON KIMBERLY H
11/20
04:25 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: JACKSON JAMERE
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: JACKSON JAMERE
11/20
04:24 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Hedley Mary Lynne
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Hedley Mary Lynne
11/20
04:23 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Fyrwald J Erik
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Fyrwald J Erik
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies [Reuters]
14.2%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
TOP News Decliners
3/11
Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors [The Motley Fool]
-10.0%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: